Skip to main content
. 2014 Feb 11;98(7):951–955. doi: 10.1136/bjophthalmol-2013-304736

Table 2 .

Ocular and serious systemic adverse events (AEs)

Ocular adverse event (%)
 Patients with ocular AEs 6 (13)
 Cataract progression 3 (7)
 Geographic atrophy progression 3 (7)
Serious adverse events (%)
 Patients with SAEs 9 (20)
 Total SAEs 11 (24)
 Death 1 (2)
 Atrial fibrillation 1 (2)
 Squamous cell carcinoma 2 (4)
 Upper respiratory tract infection 5 (11)
 Urinary tract infection 2 (4)